The efforts of Dave and the rest of the
biotech enthusiasts are having a profound
effect on the appearance of my "portfolio"
...hmmm.
I think the quality of the stocks I am holding is
going up...and the riskiness down I hope. At this
point, a quarter into the year, I find my account
is exactly where it started this year...so I'm
starting fresh, and not in the hole, so that is
good. I'll continue to hold a couple of the things
to which I've become attatched, and cant bear to take
my lumps...speaking of which I'll be posting a note
to the Ariad thread in a few minutes with something
that may interest you all.
Anyway...
Starting from the data in the valuation spreadsheet,
then taking a cold hard look at my stocks, I decided
to discard several issues...Hyseq*, Curagen*, Targeted
Genetics**...and with the proceeds I bought myself Regeneron
and Onyx (regn immediately went down 1/4 heheh, but I've
thrown in the towel on trading, I don't even open my
level II screen when I do a trade anymore...)
Gosh, I actually own four stocks off the valuation
list now...and am looking at another (with my
rotating shifts, and jet-lagged type sleepiness
a lot of the time, you can guess that after Monday's
RS call regarding Provigil...ceph does look interesting***).
So here they are...the new, refurbished,
MM-mainly-microcap biotech list...
ARIA CNSI CTII NTII SIBI ONXX REGN
(plus a couple of others generally
not followed too much by this group,
for instance just bought some MAGN).
______________
*With the recent weakness in Incyte, maybe now
is a good time not to be in any bioinformatics-
oriented stocks...you wonder if a few funds might
now have a tendency to unload anything in that sector)
**TGEN has been good to me, seems to react well
whenever a story is run in the paper. But after
downloading all the gene therapy aacr abstracts,
I find that I want to own onxx instead...nuff said.
***RS call also mentioned CEGE, I wont reveal any
more than that, but is has run a buck since last
Thursday--maybe that was all a result of RS action,
but you might want to keep an eye on the stock
for the next week, at least through the meeting.
--MM |
